Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language. A person reviews each one; registered human trials and meta-analyses that pass every automated check post without waiting for that review.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract. A person reviews them; the strongest tier — registered human trials and meta-analyses that pass every automated check — is posted first and reviewed after. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
SafetySafety & interactionsAbsorption (PK)How it's absorbed (PK)FormulationFormulation & deliverySupportive careSymptom & supportive careMetabolismMetabolism & pathwaysTrialClinical trialMechanismBiomarker & mechanism
Showing studies that mention peritoneal sarcoma.
2 of 200 studies
Case reportReported negativeLimited evidenceTier 3 · early humann = 1

Primary High-Grade Intraperitoneal Sarcoma Mimicking a Germ Cell Tumor in an 8-Year-Old Girl in Somaliland: A Diagnostic Challenge

International medical case reports journal · Jul 2026 · case report

intra-abdominal sarcomaprimary high-grade intraperitoneal sarcomapediatric abdominal tumor

This case report describes an 8-year-old girl in Somaliland who presented with a large abdominopelvic mass initially suspected to be a germ cell tumor. Empiric germ cell chemotherapy produced no response; surgery and histopathology revealed a high-grade intra-peritoneal sarcoma (desmin+, myogenin-), and the patient died about three months after treatment. The report emphasizes the diagnostic challenges when biopsy and molecular testing are limited.

Reported effects: cycles without response 2, n=1 · time to death 3 mo, n=1

Key findings
  • Imaging suggested a germ cell tumor, and empiric germ cell tumor-directed chemotherapy was started.
  • No clinical or radiological response was observed after two cycles of empiric chemotherapy.
  • Exploratory laparotomy and cytoreductive surgery identified a large intra-peritoneal mass with omental and nodal involvement.
  • Histopathology showed a high-grade malignant neoplasm with pleomorphic round-to-spindle cells and rhabdoid features; immunohistochemistry was diffusely desmin positive and myogenin negative; INI1 testing was unavailable.
  • Despite postoperative chemotherapy the disease progressed and the patient died approximately 3 months after treatment.
Limitations: Single-patient case report (n=1).; Empiric therapy was given without pre-treatment histopathological confirmation.; Incomplete diagnostic work-up: INI1 testing and other molecular diagnostics were unavailable.; Short clinical follow-up (patient died ~3 months after treatment).; Findings from one case in a resource-limited setting may not generalize..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismInconclusiveLimited evidenceTier 3 · early human

DICER1 -Associated Gynecologic Neoplasms: An Update and Review

Advances in anatomic pathology · Jan 2026 · narrative review

gynecologic neoplasmsembryonal rhabdomyosarcomaSertoli-Leydig cell tumorpleuropulmonary blastoma-like peritoneal sarcomaadenosarcomagynandroblastomajuvenile granulosa cell tumorSertoli cell tumorDICER1-related Wilms-like uterine tumor

This narrative review summarizes how germline and somatic DICER1 mutations are associated with a range of benign and malignant gynecologic neoplasms and describes their shared morphologic features. The authors note that a germline loss-of-function DICER1 mutation is often followed by a somatic hotspot (second-hit) mutation in tumors, and they recommend that recognition of characteristic morphology should prompt genetic testing and surveillance for patients and families. The review proposes the term "DICER1-related primitive polyphenotypic neoplasm" to encompass the diverse histologic features of these tumors.

Key findings
  • DICER1 is crucial for microRNA biogenesis and maturation.
  • Germline DICER1 mutations are associated with increased risk of a wide range of benign and malignant neoplasms; the same tumors can also arise sporadically via somatic DICER1 mutations.
  • In syndromic patients, a germline loss-of-function DICER1 mutation is usually followed by a somatic hotspot mutation in the tumor as a second hit.
  • DICER1-associated gynecologic neoplasms most commonly include embryonal rhabdomyosarcoma and moderately to poorly differentiated Sertoli-Leydig cell tumor, with several less frequent tumor types also described.
  • DICER1-mutant gynecologic neoplasms frequently share characteristic morphology (primitive mesenchyme, fetal-type epithelium/cartilage, rhabdomyoblastic and/or neuroectodermal differentiation, osteoid formation, and anaplasia).
  • Recognition of these distinctive morphologic features should prompt consideration of DICER1-associated neoplasm and genetic testing to facilitate surveillance for patients and families.
  • The morphologic spectrum of most DICER1-mutant gynecologic neoplasms appears wider than that of any known type of sarcoma.
  • The authors propose the term "DICER1-related primitive polyphenotypic neoplasm" to better capture the diverse histologic features.
Limitations: Narrative review without description of systematic search or methods — potential selection bias in included reports.; No primary data or quantitative synthesis (no new experimental or cohort data presented).; Extent of evidence, frequency estimates, and outcomes are not quantified in the abstract..

Summarizes the association between DICER1 mutations and a spectrum of gynecologic tumors and highlights implications for pathologic recognition and genetic testing.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed